Bladder Cancer Trial, Recruiting NCT06818136 Sponsor: Nucleix Ltd. Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT06818136
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 45 years of age or older
  • People who are willing and able to sign a consent form and follow the study procedures
  • People who have had blood in their urine (either visible or detected by testing) in the 6 months before joining the study
  • People who are already scheduled to have a camera examination of the bladder (called a cystoscopy) within 60 days of joining the study
  • People who are able to provide at least 10 ml of urine (roughly two teaspoons)

Who may not be able to join:

  • People who have a previous history of cancer in the bladder or upper urinary tract
  • People who have had a camera examination of the bladder (cystoscopy) for blood in the urine within the past 2 years
  • People who have previously taken part in this same study
  • People who have been treated for prostate cancer within the last 12 months
  • People who have been treated for kidney cancer within the last 12 months
  • People who currently have an untreated urinary tract infection
  • People who have urinary tract stones that are causing symptoms such as pain in the side or back
  • People who are on dialysis due to kidney failure
  • People who have a long-term urinary catheter in place
  • People who are pregnant (based on self-reporting)
  • People whose general health or frailty means they are not expected to be able to complete all the steps of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paramananthan Mariappan, MB BS PhD FRCS(Urol) FEBU FRCS, Western General Hospital, Edinburgh

Phone: +972-8-9161616

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Nucleix Ltd.
Registry
ClinicalTrials.gov
Start date
20 June 2025
Est. completion
1 August 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

The sensitivity and specificity of Bladder EpiCheck to detect primary urothelial carcinoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov